NASDAQ:PLSE Pulse Biosciences (PLSE) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free PLSE Stock Alerts $7.42 +0.23 (+3.20%) (As of 11:39 AM ET) Add Compare Share Share Today's Range$7.23▼$7.6950-Day Range$6.69▼$10.8852-Week Range$3.78▼$13.62Volume66,668 shsAverage Volume178,296 shsMarket Capitalization$409.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pulse Biosciences alerts: Email Address Pulse Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish17.96% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.19 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pulse Biosciences. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.96% of the float of Pulse Biosciences has been sold short.Short Interest Ratio / Days to CoverPulse Biosciences has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.Change versus previous monthShort interest in Pulse Biosciences has recently increased by 10.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePulse Biosciences has received a 61.90% net impact score from Upright. Pulse Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Diagnostic and treatment machines", "Medical devices engineering", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Pulse Biosciences is -0.60. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Pulse Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PLSE on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders69.70% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulse Biosciences has a P/B Ratio of 8.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Pulse Biosciences Stock (NASDAQ:PLSE)Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Read More PLSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLSE Stock News HeadlinesApril 28, 2024 | insidermonkey.com5 ChatGPT Penny Stock Picks Right NowApril 24, 2024 | businesswire.comPulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024April 29, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 29, 2024 | finance.yahoo.comQ4 2023 Pulse Biosciences Inc Earnings CallMarch 28, 2024 | investorplace.comPLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023March 28, 2024 | finance.yahoo.comPulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023March 28, 2024 | businesswire.comPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial ResultsMarch 28, 2024 | businesswire.comPulse Biosciences Announces Plans to Initiate a Rights OfferingApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 17, 2024 | finance.yahoo.comPLSE Apr 2024 25.000 callMarch 17, 2024 | finance.yahoo.comPLSE Oct 2024 17.500 callMarch 16, 2024 | finance.yahoo.comPLSE Oct 2024 12.500 callMarch 16, 2024 | finance.yahoo.comPLSE Jul 2024 2.500 putMarch 14, 2024 | businesswire.comPulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024March 13, 2024 | msn.comPulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearanceMarch 10, 2024 | investing.comFDA clears Pulse Biosciences' soft tissue ablation systemMarch 9, 2024 | markets.businessinsider.comPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode SystemMarch 8, 2024 | stockhouse.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode SystemMarch 8, 2024 | businesswire.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemFebruary 14, 2024 | markets.businessinsider.comPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock UpFebruary 14, 2024 | finance.yahoo.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 14, 2024 | businesswire.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 2, 2024 | finance.yahoo.comCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In GrowthJanuary 31, 2024 | finance.yahoo.comPulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF SymposiumJanuary 6, 2024 | finance.yahoo.comInsiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchasesJanuary 2, 2024 | finance.yahoo.comPulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac ClampDecember 20, 2023 | finance.yahoo.comPulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterSee More Headlines Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/29/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PLSE CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.74% Return on Assets-61.09% Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual Sales$700,000.00 Price / Sales567.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book8.88Miscellaneous Outstanding Shares55,220,000Free Float16,733,000Market Cap$397.03 million OptionableOptionable Beta1.67 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Executive Chairman Mr. Kevin P. Danahy (Age 52)President & CEO Comp: $834.73kMr. Darrin R. Uecker (Age 58)CTO & Director Comp: $834.73kMr. Mitchell E. Levinson (Age 64)Chief Strategy Officer Comp: $584.57kDr. Richard Nuccitelli Ph.D.Chief Science OfficerMr. Kenneth B. Stratton Esq. (Age 55)J.D., General Counsel & Corporate Secretary Ms. Patty PerlaVice President of Human ResourcesMr. David DanitzSenior Vice President of EngineeringDr. Gansevoort Dunnington M.D.Chief Medical OfficerDr. Niv Ad M.D.Chief Science Officer of Cardiac SurgeryMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKSurmodicsNASDAQ:SRDXNeuroPaceNASDAQ:NPCEBeauty HealthNASDAQ:SKINSeaSpineNASDAQ:SPNEView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 1,900 shares on 4/25/2024Ownership: 0.000%Westside Investment Management Inc.Sold 2,015 shares on 4/19/2024Ownership: 0.058%Griffin Asset Management Inc.Bought 40,700 shares on 4/17/2024Ownership: 0.544%PNC Financial Services Group Inc.Bought 19,789 shares on 3/22/2024Ownership: 0.036%Tower Research Capital LLC TRC Sold 7,991 shares on 2/13/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions PLSE Stock Analysis - Frequently Asked Questions How have PLSE shares performed in 2024? Pulse Biosciences' stock was trading at $12.24 on January 1st, 2024. Since then, PLSE stock has decreased by 41.3% and is now trading at $7.19. View the best growth stocks for 2024 here. When is Pulse Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our PLSE earnings forecast. How can I listen to Pulse Biosciences' earnings call? Pulse Biosciences will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc. (NASDAQ:PLSE) posted its earnings results on Thursday, March, 28th. The company reported ($0.21) earnings per share for the quarter. What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO? 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX). When did Pulse Biosciences IPO? Pulse Biosciences (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO. Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (0.54%), Westside Investment Management Inc. (0.06%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLSE) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
